Householder Group Estate & Retirement Specialist LLC Reduces Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Householder Group Estate & Retirement Specialist LLC cut its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 30.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 742 shares of the biopharmaceutical company’s stock after selling 323 shares during the period. Householder Group Estate & Retirement Specialist LLC’s holdings in Gilead Sciences were worth $68,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Massachusetts Financial Services Co. MA boosted its position in Gilead Sciences by 0.6% in the second quarter. Massachusetts Financial Services Co. MA now owns 85,804 shares of the biopharmaceutical company’s stock worth $5,887,000 after purchasing an additional 522 shares during the last quarter. Seven Eight Capital LP purchased a new position in Gilead Sciences in the second quarter worth about $525,000. MQS Management LLC boosted its position in Gilead Sciences by 33.9% in the second quarter. MQS Management LLC now owns 4,573 shares of the biopharmaceutical company’s stock worth $314,000 after purchasing an additional 1,157 shares during the last quarter. Ieq Capital LLC boosted its position in Gilead Sciences by 3.7% in the second quarter. Ieq Capital LLC now owns 69,215 shares of the biopharmaceutical company’s stock worth $4,749,000 after purchasing an additional 2,453 shares during the last quarter. Finally, Canada Pension Plan Investment Board boosted its position in Gilead Sciences by 91.4% in the second quarter. Canada Pension Plan Investment Board now owns 2,699,863 shares of the biopharmaceutical company’s stock worth $185,238,000 after purchasing an additional 1,289,420 shares during the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, Director Jeffrey Bluestone sold 6,788 shares of the business’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total transaction of $620,355.32. Following the completion of the transaction, the director now owns 8,920 shares in the company, valued at $815,198.80. The trade was a 43.21 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Andrew D. Dickinson sold 248,645 shares of the business’s stock in a transaction on Friday, November 29th. The shares were sold at an average price of $92.76, for a total value of $23,064,310.20. Following the transaction, the chief financial officer now owns 138,919 shares of the company’s stock, valued at approximately $12,886,126.44. The trade was a 64.16 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 456,234 shares of company stock valued at $42,130,461. 0.29% of the stock is currently owned by insiders.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $91.84 on Friday. The company has a market cap of $114.46 billion, a P/E ratio of 1,020.44, a P/E/G ratio of 1.27 and a beta of 0.18. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. The business’s 50 day moving average price is $91.75 and its 200-day moving average price is $83.97. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $98.90.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating the consensus estimate of $1.58 by $0.44. The firm had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The company’s revenue for the quarter was up 7.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.29 EPS. Sell-side analysts predict that Gilead Sciences, Inc. will post 4.36 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, December 30th. Stockholders of record on Friday, December 13th were given a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a dividend yield of 3.35%. The ex-dividend date was Friday, December 13th. Gilead Sciences’s dividend payout ratio is currently 3,422.22%.

Analysts Set New Price Targets

Several research analysts have issued reports on GILD shares. Piper Sandler raised their target price on Gilead Sciences from $95.00 to $105.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. JPMorgan Chase & Co. lifted their price objective on Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Truist Financial lifted their price objective on Gilead Sciences from $83.00 to $97.00 and gave the company a “hold” rating in a research report on Friday, November 8th. Sanford C. Bernstein assumed coverage on Gilead Sciences in a research report on Thursday, October 17th. They set an “outperform” rating and a $105.00 price objective on the stock. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and set a $84.00 price objective on shares of Gilead Sciences in a research report on Wednesday, December 11th. Eleven analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $97.96.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.